Clinical Trial Update: Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study assessing the safety and tolerability of PCI-32765 (ibrutinib) in patients with recurrent B-cell lymphoma or B-cell leukemia; the trial has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia
• B-cell Lymphoma

Drugs mentioned

• PCI-32765 (ibrutinib)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: B-Cell Lymphoma, B-Cell Leukemia | Phase 1 | Status: COMPLETED